Last updated: October 23, 2026
PEPCID Preservative Free is the injectable famotidine formulation historically marketed under Merck’s Pepcid brand. Its commercial profile differs from over-the-counter Pepcid tablets and chewables. The injectable product operates in a hospital generic market, has no meaningful remaining U.S. patent protection, and has no separately reported revenue line. Its financial trajectory is therefore driven by hospital demand, generic competition, supply reliability, contracting, and the status of the branded product in FDA records rather than by exclusivity or consumer-brand growth.
What is PEPCID Preservative Free?
PEPCID Preservative Free is famotidine injection, supplied as a preservative-free intravenous formulation. The product is used to reduce gastric acid secretion in conditions including active duodenal ulcer, gastric ulcer, gastroesophageal reflux disease, and pathological hypersecretory conditions when oral administration is not practical. The labeled product is generally supplied at a concentration of 10 mg/mL for intravenous use.[1]
The product is distinct from:
- Pepcid AC tablets and chewables
- Pepcid Complete antacid and acid-reducer products
- Generic famotidine tablets
- Generic famotidine injection supplied by hospital injectable manufacturers
The injectable formulation is administered in hospitals and other institutional settings. It is not a major retail pharmacy product.
Product profile
| Attribute |
PEPCID Preservative Free |
| Active ingredient |
Famotidine |
| Dosage form |
Intravenous injection |
| Typical concentration |
10 mg/mL |
| Preservative status |
Preservative free |
| Regulatory pathway |
NDA 019510 historically associated with Pepcid injection |
| Primary customers |
Hospitals, health systems, wholesalers |
| Therapeutic class |
Histamine-2 receptor antagonist |
| Main alternatives |
Generic famotidine injection, IV proton-pump inhibitors |
| U.S. patent position |
Core composition and use patents expired |
| Revenue disclosure |
Not separately reported by Merck |
What is the FDA regulatory and Orange Book status of PEPCID Preservative Free?
The original Pepcid injection product was approved under a New Drug Application held by Merck-related entities. FDA product records and labeling identify famotidine injection as an established prescription product.[1,2]
The commercial status must be separated from the existence of labeling. A DailyMed label can remain accessible after a product changes commercial status, and an FDA record does not by itself establish current sales volume. The public regulatory record does not support a material, separately reported active branded revenue stream for PEPCID Preservative Free.
Orange Book position
The Orange Book’s economic relevance is limited because famotidine’s core patent estate expired decades ago. The branded injectable product does not have a modern, commercially meaningful period of Orange Book exclusivity comparable to newer specialty drugs.
| Regulatory factor |
Assessment |
| New chemical entity exclusivity |
Expired |
| Core famotidine composition patent |
Expired |
| Injectable formulation exclusivity |
No material current exclusivity identified |
| Pediatric exclusivity |
Not a current commercial barrier |
| Paragraph IV exposure |
Historically relevant during generic entry, not a current branded defense |
| Generic approval pathway |
ANDA-based competition is available |
| Current patent-based launch barrier |
Low |
When did PEPCID Preservative Free lose exclusivity?
Famotidine was discovered and developed in the 1970s. The core U.S. patent estate expired before the current decade and no longer supports a protected branded market.
The primary U.S. famotidine patent was U.S. Patent No. 4,283,408, assigned to Merck and covering famotidine and related pharmaceutical compositions. Its expiration occurred in the 1990s, subject to the patent-term rules applicable at the time.[3] Any remaining commercial value comes from manufacturing scale, supply contracts, brand recognition, and hospital procurement rather than molecule-level exclusivity.
Exclusivity timeline
| Period |
Event |
Market effect |
| 1970s |
Famotidine discovery and development |
Created the originator opportunity |
| 1980s |
Pepcid launched in major markets |
Established the branded franchise |
| Early 1990s |
U.S. patent protection approached expiry |
Generic-entry risk increased |
| Mid-to-late 1990s |
Generic famotidine became available |
Branded pricing power declined |
| 2000s |
Injectable famotidine became a multisupplier hospital product |
Contracting and supply became central |
| 2019 |
Merck completed the consumer-health transaction with Procter & Gamble |
Consumer Pepcid economics separated from Merck’s prescription portfolio |
| 2020 |
Ranitidine withdrawal increased famotidine demand temporarily |
Shortage and allocation pressure affected supply |
| 2021 onward |
Demand normalized |
Market returned to mature generic dynamics |
How large is the PEPCID Preservative Free market?
No public company reports PEPCID Preservative Free revenue as a separate line item. Market size must therefore be estimated from the broader famotidine injection segment, hospital purchasing data, and supplier disclosures.
The addressable market is relatively narrow because:
- Famotidine is generic and inexpensive.
- Hospitals can substitute among multiple suppliers.
- Intravenous acid suppression competes with proton-pump inhibitors.
- The product is typically purchased through group purchasing organizations and wholesalers.
- The brand carries limited incremental clinical value over generic famotidine injection.
The market is best characterized as a low-growth, price-sensitive institutional segment. Unit demand is relatively stable, while dollar revenue depends on supply disruptions and contract pricing.
Demand drivers
Hospital demand is supported by:
- Use in patients unable to take oral medication
- Perioperative and inpatient acid suppression
- Critical-care protocols
- Temporary substitution for oral H2 blockers
- Ranitidine discontinuation after FDA-requested market withdrawal
- Periodic shortages of competing injectable products
Demand is limited by:
- Broad generic availability
- Clinical substitution with IV pantoprazole and other proton-pump inhibitors
- Reduced use of routine stress-ulcer prophylaxis in some hospital protocols
- Low reimbursement leverage for an old generic molecule
- Preference for lower-cost contract suppliers
What caused the 2020 Pepcid demand spike?
Famotidine demand increased sharply in 2020 after public discussion of possible COVID-19-related benefits. The increase was not based on an established FDA-approved COVID-19 indication. Hospitals and wholesalers also increased purchasing because ranitidine had been removed from the market over N-nitrosodimethylamine contamination concerns.[4,5]
The 2020 market effect had three components:
| Driver |
Effect |
| Ranitidine withdrawal |
Shifted H2-blocker demand toward famotidine |
| COVID-19 speculation |
Increased ordering and inventory building |
| Hospital stockpiling |
Tightened supply and caused temporary allocation |
This episode likely increased short-term unit shipments and supplier revenue, but it did not create durable pricing power. Once clinical evidence failed to establish famotidine as a COVID-19 treatment and inventories normalized, demand returned toward baseline.
Which companies compete with PEPCID Preservative Free?
The relevant competitors are generic injectable-famotidine suppliers and manufacturers of alternative IV acid-suppression therapies.
Direct competitors
The direct market includes generic famotidine injection from suppliers such as:
- Hikma Pharmaceuticals
- Fresenius Kabi
- Sagent Pharmaceuticals or its successor commercial structures
- Other approved ANDA holders and contract manufacturers
Supplier participation can change because injectable products are periodically discontinued, transferred, or placed on shortage allocation. Hospital buyers often maintain more than one approved source.
Therapeutic competitors
| Product class |
Examples |
Competitive effect |
| H2 antagonists |
Generic famotidine injection |
Direct substitution |
| Proton-pump inhibitors |
Pantoprazole injection, omeprazole injection |
Strong institutional alternative |
| Oral or enteral acid reducers |
Famotidine tablets, lansoprazole, omeprazole |
Reduce need for IV treatment |
| Formulary protocols |
Hospital-specific stress-ulcer pathways |
Determine utilization |
Pantoprazole is the most important therapeutic competitor in many hospital formularies. The competition is generally based on protocol, acquisition cost, availability, and administration convenience rather than brand differentiation.
What patent litigation and Paragraph IV challenges affect the product?
No active, material patent litigation is central to the present commercial position of PEPCID Preservative Free. The main generic-entry litigation risk occurred during the period when famotidine’s composition and product patents were approaching expiry.
Because the relevant patent protection expired long ago, a new Paragraph IV challenge would not create a meaningful strategic event for the originator product. Generic applicants can compete through ANDA pathways without confronting a current blocking patent estate of commercial significance.
Litigation assessment
| Issue |
Current assessment |
| Active composition-patent litigation |
No material current dispute identified |
| Active formulation-patent litigation |
No material current dispute identified |
| Paragraph IV settlements |
Historic generic-entry issue |
| Authorized generic strategy |
Not a meaningful current differentiator |
| Injunction risk |
Low |
| Launch-at-risk exposure |
Low for the mature product |
What formulations are protected by PEPCID Preservative Free patents?
The original product’s formulation and injectable presentation may have been covered by historical product and formulation claims. Those claims no longer create a meaningful market barrier.
The commercial formulation remains technically relevant because injectable famotidine must meet requirements for:
- Sterility
- Stability
- Container closure integrity
- Low particulate burden
- Appropriate pH and compatibility
- Controlled manufacturing conditions
- Preservative-free packaging suitable for intravenous administration
These requirements create manufacturing and quality barriers, but they are regulatory and operational barriers rather than durable patent barriers.
Manufacturing and IP barriers
The remaining barriers include:
- FDA-compliant sterile fill-finish capacity
- Reliable supply of active pharmaceutical ingredient
- Validation of aseptic processes
- Hospital qualification and vendor approval
- Shortage-management capability
- Wholesaler and group-purchasing contracts
These barriers can protect market share temporarily, particularly during shortages. They do not support premium pricing over the long term.
How strong is the patent estate for PEPCID Preservative Free?
The patent estate is weak from a current commercial perspective.
| Patent-estate dimension |
Strength |
| Composition-of-matter protection |
None remaining |
| Primary therapeutic-use protection |
None commercially material |
| Injectable formulation protection |
Limited or expired |
| Device protection |
Not central to the product |
| Manufacturing-process protection |
Potentially narrow and nonblocking |
| Freedom to market generic famotidine injection |
Broad |
| Ability to exclude competitors |
Minimal |
The product’s defensibility depends on execution. A supplier with reliable sterile manufacturing, consistent fill rates, and favorable hospital contracts can retain share. A supplier cannot rely on patent exclusivity to prevent competitive entry.
What is the financial trajectory for PEPCID Preservative Free?
The financial trajectory is mature-to-declining on a branded basis, with temporary volume upside during supply disruptions.
Revenue phases
| Phase |
Financial profile |
| Branded launch and early maturity |
High-margin originator economics |
| Generic entry |
Rapid price erosion and share loss |
| Mature hospital market |
Low-price, volume-driven revenue |
| 2020 disruption |
Temporary demand and pricing increase |
| Post-2020 normalization |
Lower, stable, or declining branded economics |
| Current outlook |
Limited standalone revenue growth |
Merck does not report PEPCID Preservative Free as a standalone product. The product’s contribution is therefore immaterial or embedded within broader prescription-product reporting. Consumer Pepcid revenue after the Merck-Procter & Gamble transaction should not be attributed to the injectable product.[6]
Revenue exposure
The most plausible financial conclusion is:
- No meaningful patent premium remains.
- Standalone brand revenue is not publicly visible.
- Hospital injectable revenue is exposed to generic price competition.
- Shortage events can produce temporary revenue increases.
- Long-term growth depends on volume retention, not price expansion.
- The product has limited strategic value compared with newer branded medicines.
What generic launch scenarios exist?
Base case: continued mature generic competition
Generic suppliers retain the majority of institutional volume. Prices remain constrained by contracts and formulary substitution. The branded product has little ability to increase share without a supply disruption.
Upside case: competitor shortage
A shortage affecting generic famotidine injection or IV proton-pump inhibitors can increase demand for available inventory. The effect is usually temporary and may be constrained by allocation rules and hospital purchasing agreements.
Downside case: branded withdrawal or reduced availability
If the branded product is discontinued or no longer actively supplied, hospitals can transition to generic famotidine injection with limited clinical disruption. The substitution risk is high because the active ingredient, route, and concentration are standardized.
Structural downside: IV-to-oral substitution
Improved oral or enteral access can reduce demand for injectable acid suppression. This is a gradual volume risk rather than a sudden patent-driven event.
How does PEPCID Preservative Free compare with consumer Pepcid?
| Factor |
PEPCID Preservative Free |
Consumer Pepcid |
| Dosage form |
IV injection |
Tablets, chewables, combination products |
| Customer |
Hospitals and health systems |
Retail consumers |
| Primary owner context |
Historically Merck prescription business |
Consumer-health business transferred to P&G and later associated with Kenvue |
| Pricing |
Contract and tender driven |
Retail and brand driven |
| Patent value |
Minimal |
Brand recognition is more important than patents |
| Growth driver |
Hospital volume and supply |
Consumer awareness, heartburn prevalence, retail distribution |
| Financial disclosure |
Not separately reported |
Consumer-brand sales may be included in broader consumer-health reporting |
| Substitution |
Generic injection and IV PPIs |
Generic famotidine and competing OTC acid reducers |
The consumer brand can retain value through advertising and shelf presence. The injectable product cannot rely on the same economics.
Key Takeaways
- PEPCID Preservative Free is an injectable famotidine product for institutional use, not the retail Pepcid franchise.
- The core famotidine patent estate expired decades ago.
- No meaningful current Orange Book exclusivity protects the injectable product.
- Generic famotidine injection and IV proton-pump inhibitors are the principal competitors.
- The product has no separately disclosed revenue stream.
- The 2020 demand spike was temporary and reflected ranitidine withdrawal, COVID-19-related purchasing, and hospital stockpiling.
- Current economics are controlled by hospital contracts, sterile manufacturing, supply reliability, and shortages.
- The commercial outlook is mature and price-sensitive, with limited potential for durable revenue growth.
- A generic launch would face low patent risk and high substitution potential.
- Formulation and sterile-manufacturing requirements create operational barriers, not strong exclusionary IP.
FAQs
Is PEPCID Preservative Free still marketed in the United States?
The product has historical FDA labeling and an established regulatory record, but public information does not support a material standalone branded U.S. revenue stream. Hospital use can be supplied through generic famotidine injection.
Does PEPCID Preservative Free have an active patent?
No commercially meaningful core patent protection remains. Famotidine’s composition patents expired in the 1990s.
Can a generic manufacturer launch famotidine injection?
Yes. Generic famotidine injection can be approved through the ANDA pathway, subject to FDA requirements for bioequivalence, sterility, manufacturing quality, and product specifications.
Is famotidine injection exposed to biosimilar competition?
No. Famotidine is a chemically synthesized small molecule, not a biologic. The relevant competitive pathway is generic-drug approval, not biosimilar approval.
What is the largest commercial risk for injectable famotidine?
The largest risk is sustained price erosion combined with hospital substitution to generic famotidine or IV proton-pump inhibitors. Shortages can temporarily improve pricing and volume but do not create durable exclusivity.
References
- U.S. National Library of Medicine. (n.d.). Pepcid injection: Famotidine injection prescribing information. DailyMed.
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs, Pepcid and famotidine injection records.
- U.S. Patent and Trademark Office. (1981). U.S. Patent No. 4,283,408: Famotidine.
- U.S. Food and Drug Administration. (2020). FDA requests removal of all ranitidine products from the market.
- National Institutes of Health. (2020). Famotidine and COVID-19: Clinical evidence and ongoing evaluation. ClinicalTrials.gov.
- Procter & Gamble. (2019). Procter & Gamble completes transaction with Merck for consumer health products.
